0001171843-22-003460.txt : 20220509 0001171843-22-003460.hdr.sgml : 20220509 20220509163035 ACCESSION NUMBER: 0001171843-22-003460 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220509 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220509 DATE AS OF CHANGE: 20220509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aptose Biosciences Inc. CENTRAL INDEX KEY: 0000882361 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32001 FILM NUMBER: 22905508 BUSINESS ADDRESS: STREET 1: 251 CONSUMERS ROAD STREET 2: SUITE 1105 CITY: TORONTO STATE: A6 ZIP: M2J 4R3 BUSINESS PHONE: 647-479-9828 MAIL ADDRESS: STREET 1: 251 CONSUMERS ROAD STREET 2: SUITE 1105 CITY: TORONTO STATE: A6 ZIP: M2J 4R3 FORMER COMPANY: FORMER CONFORMED NAME: Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.) DATE OF NAME CHANGE: 20140905 FORMER COMPANY: FORMER CONFORMED NAME: LORUS THERAPEUTICS INC DATE OF NAME CHANGE: 19990308 FORMER COMPANY: FORMER CONFORMED NAME: IMUTEC PHARMA INC DATE OF NAME CHANGE: 19970113 8-K 1 f8k_050922.htm FORM 8-K Form 8-K
0000882361 False 0000882361 2022-05-09 2022-05-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  May 9, 2022

_______________________________

Aptose Biosciences Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Canada001-3200198-1136802
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

251 Consumers Road, Suite 1105

Toronto, Ontario Canada M2J 4R3

(Address of Principal Executive Offices) (Zip Code)

(647) 479-9828

(Registrant's telephone number, including area code)

 

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Shares, no par valueAPTONasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 2.02. Results of Operations and Financial Condition.

 

On May 9, 2022, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.
   
Exhibit 99.1 Press Release dated May 9, 2022
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Aptose Biosciences Inc.
   
  
Date: May 9, 2022By: /s/ William G. Rice, Ph.D.        
  William G. Rice, Ph.D.
  Chairman, President and Chief Operating Officer
  

 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Aptose Reports Results for the First Quarter 2022

Expands HM43239 dose cohort at 160 mg

Headway with luxeptinib “G3” formulation in patients

Conference call and webcast at 5:00 pm ET today

SAN DIEGO and TORONTO, May 09, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results for the three months ended March 31, 2022 and provided a corporate update.

The net loss for the quarter ended March 31, 2022 was $11.5 million ($0.12 per share) compared with $16.2 million ($0.18 per share) for the quarter ended March 31, 2021. Total cash and cash equivalents and investments as of March 31, 2022 were $69.5 million. Based on current operations, Aptose expects that cash on hand and available capital provide the Company with sufficient resources to fund all planned Company operations including research and development into the fourth quarter of 2023.

“Aptose has two meaningful clinical-stage kinome inhibitors in HM43239 and luxeptinib, and we continue to advance their development in distinct patient populations,” said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer. “To date, both have demonstrated clear activity and have been well-tolerated. As we define the next steps in the development program with our lead compound HM43239, we are encouraged by the clinical remissions we are seeing in AML patients, particularly in those with highly adverse mutations that typically are difficult to treat but respond to HM43239. We look forward to reporting all available data on our programs at an upcoming corporate event.”

Key Corporate Highlights

  • Aptose Receives Fast Track Designation for HM43239 – The U.S. Food and Drug Administration (FDA) granted Fast Track designation to HM43239 (239), an oral, myeloid kinome inhibitor, for the treatment of patients with relapsed, refractory (R/R) acute myeloid leukemia (AML) who have FLT3 mutations. Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.The purpose is to get important new drugs to patients earlier.

  • HM43239 Expansion at 160 mg in Diverse AML Patient Population – HM43239, an oral, myeloid kinome inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML), thus far has delivered six composite complete remissions (CR) and a PR at the 80 mg and 120 mg doses. Aptose is now expanding at the 160 mg dose level, with the goal of understanding the breadth of activity of 239 in diverse mutations and identifying the best efficacious and safe doses to treat relapsed and refractory AML. HM43239 thus far has demonstrated a favorable safety profile with no DLTs and no drug discontinuations from drug related toxicity at doses up to 160 mg per day.  

  • Headway with Luxeptinib “G3” Formulation in Patients – Luxeptinib , a dual lymphoid and myeloid kinome inhibitor, currently is being evaluated in a Phase 1 a/b study in patients with relapsed or refractory AML and higher risk MDS, and in a separate Phase 1 a/b study in patients with relapsed or refractory B-cell malignancies. Aptose has made significant progress with the clinical evaluation of a new formulation of luxeptinib (Lux), that may enable greater exposures across patients. In the ongoing studies in AML and B-cell malignancies, a dose of the G3 formulation has been safely administered to three patients at the 50 mg dose level and is now being dosed at the 100 mg dose level. After patients receive the single G3 dose, samples are collected for PK evaluation and patients then go onto the original formulation of Lux for comparison.

  • Aptose Appoints Chief Commercial Officer – Aptose recently appointed Dr. Philippe Ledru to the position of Chief Commercial Officer, responsible for providing executive leadership and vision for commercial development and marketing strategies for the future commercial launches of HM43239 and luxeptinib and to consolidate responsibilities over business development and licensing. Dr. Ledru most recently served as Associate Vice President and Head of Oncology New Products at Merck & Co., over 25 assets from discovery to mid-stage clinical development, across major solid tumors and hematological malignancies At Merck, he also provided leadership on all licensing and M&A activities, including the Peloton Therapeutics and Arqule acquisitions in 2019. Earlier, at Novartis, he had early commercial development and global marketing responsibilities for several new compounds, including FLT3 inhibitor midostaurin, and at Novartis Oncologie he helped lead launches of several oncology products, including imatinib (Gleevec).

RESULTS OF OPERATIONS  

A summary of the results of operations for the three-month periods ended March 31, 2022 and 2021 is presented below:

 Three months ended March 31, 
(in thousands except per Common Share data) 2022   2021  
       
Revenues$-  $-  
Research and development expenses 7,393   8,228  
General and administrative expenses 4,107   8,024  
Net finance income 19   25  
Net loss and comprehensive loss$(11,481) $(16,227) 
Basic and diluted loss per Common Share$(0.12) $(0.18) 
       

The net loss for the three-month period ended March 31, 2022, decreased by $4.7 million to $11.5 million as compared with $16.2 million for the comparable period in 2021. Components of the net loss are presented below:

Research and Development

Research and development expenses consist primarily of costs incurred related to the research and development of our product candidates. Costs include the following:

  • External research and development expenses incurred under agreements with third parties, such as CROs, consultants, members of our scientific advisory boards, external labs and CMOs; and

  • Employee-related expenses, including salaries, benefits, travel, and stock-based compensation for personnel directly supporting our clinical trials and manufacturing, and development activities.

We have ongoing Phase 1 clinical trials for our product candidates HM43239 and Luxeptinib. HM43239 was licensed into Aptose in Q4, 2021 and we have assumed sponsorship, and the related costs, of the HM43239 study effective January 1, 2022. In Q4, 2021, we discontinued the APTO-253 program and are exploring strategic alternatives for this compound.

We expect our research and development expenses to be higher for the foreseeable future as we continue to advance HM43239 and luxeptinib into larger clinical trials.

The research and development expenses for the three-month periods ended March 31, 2022, and 2021 were as follows:

  Three months ended March 31, 
(in thousands)  2022  2021 
        
        
Program costs – HM43239  1,178  - 
Program costs – Luxeptinib  2,830  3,971 
Program costs – APTO-253  91  1,090 
Personnel expenses  2,334  1,788 
Stock-based compensation  946  1,378 
Depreciation of equipment  14  1 
  $7,393 $8,228 
        

Research and development expenses decreased by $835 thousand to $7.4 million for the three-month period ended March 31, 2022 as compared with $8.2 million for the comparative period in 2021. Changes to the components of our research and development expenses presented in the table above are primarily as a result of the following events:

  • Program costs for HM43239 increased by approximately $1.2 million as the Company in-licensed the development rights of HM43239 in the fourth quarter of 2021 and assumed sponsorship, and the related costs, of the study effective January 1, 2022.

  • Program costs for luxeptinib decreased by approximately $1.1 million, primarily due to lower manufacturing costs as a result of the current formulation requiring less API than the prior formulation and also from lower clinical trial costs, mostly related to fewer contractors needed to support the trials.

  • Program costs for APTO-253 decreased by approximately $1.0 million, due to the Company’s decision on December 20, 2021 to discontinue further clinical development of APTO-253.

  • Personnel-related expenses increased by $546 thousand, mostly related to new positions hired in 2021 to support our clinical trials and manufacturing activities.

  • Stock-based compensation decreased by approximately $432 thousand in the three months ended March 31, 2022, compared with the three months ended March 31, 2021, primarily due to lower grant date fair value of options which were granted in the current period.

General and Administrative

General and administrative expenses consist primarily of salaries, benefits and travel, including stock-based compensation for our executive, finance, business development, human resource, and support functions. Other general and administrative expenses are professional fees for auditing, and legal services, investor relations and other consultants, insurance and facility related expenses.

We expect that our general and administrative expenses will increase for the foreseeable future as we incur additional costs to support the expansion of our pipeline of activities. We also expect our intellectual property related legal expenses to increase as our intellectual property portfolio expands.

The general and administrative expenses for the three-month periods ended March 31, 2022 and 2021 were as follows:

  Three months ended March 31,
(in thousands)  2022  2021
       
General and administrative, excluding items below: $2,521 $2,725
Stock-based compensation  1,568  5,265
Depreciation of equipment  18  34
  $4,107 $8,024
       

General and administrative expenses for the three-month period ended March 31, 2022 were $4.1 million as compared with $8.0 million for the comparative period in 2021, a decrease of approximately $3.9 million. The decrease was primarily as a result of the following:

  • General and administrative expenses, other than stock-based compensation and depreciation of equipment, decreased by approximately $204 thousand in the three months ended March 31, 2022 primarily as a result lower professional fees.

  • Stock-based compensation decreased by approximately $3.7 million in the three months ended March 31, 2022, compared with the three months ended March 31, 2021, primarily due to lower grant date fair value of options which were granted in the current period, and additional compensation recognized in the comparative period for modifications made to then vested and unvested stock options for one officer, as part of a separation and release agreement.

COVID-19 did not have a significant impact on our results of operations for the three-month period ended March 31, 2022. We have not experienced and do not foresee material delays to the enrollment of patients or timelines for the HM43239 Phase 1/2 trial or the luxeptinib Phase 1a/b trials due to the variety of clinical sites that we have actively recruited for these trials. As of the date of this report, we have not experienced material delays in the manufacturing of HM43239 or luxeptinib related to COVID-19. Should our manufacturers be required to shut down their facilities due to COVID-19 for an extended period of time, our trials may be negatively impacted.

Conference Call and Webcast

Aptose will host a conference call to discuss results for the quarter ended March 31, 2022 today, Monday, May 9, 2022 at 5:00 PM ET. Participants can access the conference call by dialing 1-866-374-5140 (North American toll-free number) and 1-404-400-0571 (international/toll number) and using conference ID 38238231#. The conference call can be accessed here and will also be available through a link on the Investor Relations section of Aptose’s website at https://ir.aptose.com/. An archived version of the webcast will be available on the Company’s website for 30 days. 

The press release, the financial statements and the management’s discussion and analysis for the quarter ended March 31, 2021 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml.  

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: HM43239, an oral, myeloid kinome inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral, dual lymphoid and myeloid kinome inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory B cell malignancies who have failed or are intolerant to standard therapies, and in a separate Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS). For more information, please visit www.aptose.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements regarding the expected cash runway of the Company, the clinical development plans and dose escalations, the clinical potential, anti-cancer activity, therapeutic potential and applications and safety profile of HM43239 and luxeptinib, the potential expansion of the list of the treatable population for HM43239, the HM43239 Phase 1/2 AML clinical trial, the luxeptinib Phase 1 a/b B-cell malignancy and Phase 1 a/b AML clinical trials and the upcoming milestones of such trials, the development of a new formulation (G3) for luxeptinib, expected increases in R&D, general and administratives and intellectual property related legal expenses, impacts of COVID-19 on the Company, its results and its clinical trials, upcoming updates regarding the clinical trials, the exploration of strategic alternatives for the APTO-253 program and operations and statements relating to the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “hope” “should”, “would”, “may”, “potential” and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market and economic conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; the potential impact of the COVID-19 pandemic and other risks detailed from time-to-time in our ongoing current reports, quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

For further information, please contact: 
  
Aptose Biosciences Inc.LifeSci Advisors, LLC
Susan Pietropaolo  Dan Ferry, Managing Director
Corporate Communications & Investor Relations  617-535-7746
201-923-2049Daniel@LifeSciAdvisors.com 
spietropaolo@aptose.com  

 EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
May 09, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 09, 2022
Entity File Number 001-32001
Entity Registrant Name Aptose Biosciences Inc.
Entity Central Index Key 0000882361
Entity Tax Identification Number 98-1136802
Entity Incorporation, State or Country Code Z4
Entity Address, Address Line One 251 Consumers Road, Suite 1105
Entity Address, City or Town Toronto
Entity Address, State or Province ON
Entity Address, Postal Zip Code M2J 4R3
City Area Code 647
Local Phone Number 479-9828
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol APTO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 f8k_050922_htm.xml IDEA: XBRL DOCUMENT 0000882361 2022-05-09 2022-05-09 iso4217:USD shares iso4217:USD shares 0000882361 false 8-K 2022-05-09 Aptose Biosciences Inc. Z4 001-32001 98-1136802 251 Consumers Road, Suite 1105 Toronto ON M2J 4R3 647 479-9828 false false false false Common Shares, no par value APTO NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_050922.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_050922.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "inline": { "local": [ "f8k_050922.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_050922.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_050922.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001171843-22-003460-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-22-003460-xbrl.zip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